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ABSTRACT
Background. Aggressive fibromatosis (AF) is a locally
infiltrating soft-tissue tumor. In a population-based study in
the Netherlands, we evaluated time trends for the incidence
and treatment of AF.
Methods. In PALGA: Dutch Pathology Registry, all
patients diagnosed between 1993 and 2013 as having extra-
abdominal or abdominal wall aggressive fibromatosis were
identified and available pathology data of the patients were
evaluated. Epidemiological and treatment-related factors
were analyzed with v2and regression analysis.
Results. During the study period, 1134 patients were
identified. The incidence increased from 2.10 to 5.36 per
million people per year. Median age at the time of diag-
nosis increased annually by B 0.285 (P = 0.001). Female
gender prevailed and increased over time [annual odds
ratio (OR) 1.022; P = 0.058]. All anatomic localizations,
but in particular truncal tumors, became more frequent.
During the study period diagnostic histological biopsies
were performed more often (annual OR 1.096; P\ 0.001).
The proportion of patients who underwent surgical treat-
ment decreased (annual OR 0.928; P\ 0.001). When
resection was preceded by biopsy, 49.8 % of the patients
had R0-resection versus 30.7 % in patients without biopsy
(P\ 0.001).
Conclusions. In this population-based study, an increasing
incidence of extra-abdominal and abdominal-wall
aggressive fibromatosis was observed. The workup of
patients improved and a trend towards a nonsurgical
treatment policy was observed.
Aggressive fibromatosis (AF; or desmoid-type fibro-
matosis) is a rare soft-tissue tumor that lacks the capacity to
metastasize but may behave in a locally aggressive fashion.
Knowledge on its epidemiology and etiology is limited.
The Wingless/Wnt-pathway is involved although the
mechanism is not fully understood.1–3 Three different
subtypes are recognized as entities in the WHO-classifi-
cation of desmoid-type fibromatose: extra-abdominal,
abdominal, and intra-abdominal tumors.4 The first two
mostly occur sporadic, whereas the latter has a correlation
with familiar adenomatous polyposis (FAP).5
The incidence of AF was reported previously by
Reitamo et al. in 1982, estimated at 2.4–4.3 per million
people per year.6 Their studies on the etiology and epi-
demiology often are referred to in the current literature.6–8
The correlation of intra-abdominal AF with FAP has been
subject of more recent studies.9–11 Current research on AF
mainly focuses on treatment strategies. Surgery has until
recently been the primary treatment modality. Data regard-
ing the prognostic value of surgical margins and adjuvant
radiotherapy is conflicting.12–15 New insights suggest that
asymptomatic patients can be carefully watched without
active treatment, and this is suggested by international
(NCCN and ESMO) guidelines.16,17 Symptomatic patients
with tumors that can be resected completely with acceptable
morbidity should be offered surgery. In patients with
symptomatic and ‘‘unresectable’’ disease, radiotherapy may
be considered.18 Isolated limb perfusion can be considered
for irresectable AF of the extremities.19 Systemic treatment
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also can be considered, although response rates are rather
low.20–22
We evaluated time trends of the incidence and treatment
of extra-abdominal and abdominal wall AF within the
Dutch population.
METHODS
Data Collection
The Dutch Pathology Registry PALGA was searched
for patients with extra-abdominal or abdominal AF,
whereas patients with intra-abdominal tumors were
excluded.23 The epidemiology and treatment of intra-ab-
dominal tumors are linked to FAP and are considered a
different entity. Data on this entity in the Dutch popula-
tion have been analyzed recently.9 The PALGA database
contains encoded excerpts of all pathology examinations
obtained by a diagnostic procedure, including tissue
biopsy or resection since 1979 in selected laboratories and
expanded to nationwide inclusion in 1991. The conclusion
sections of all pathology reports were queried for avail-
able information concerning patient, tumor, and treatment
characteristics. Age was categorized as\20, 20–44, 45–
64, 65–79, and [80 years old. Tumor localization was
categorized as head/neck, trunk (including breast, thoracic
aperture and back), abdominal wall, extremity, and others.
Reports were scored based on the encoding of procedures
and details in the report as biopsy, resection or re-resec-
tion and on manifestation of the tumor (primary or
recurrence). All patients undergoing re-resection were
considered to have had a prior resection, even when
pathology reports of the resection were missing. In case of
patient records documenting recurrent disease, an attempt
was made to retrieve details on the primary tumor. Due to
incomplete data registration, patients with disease pre-
sentation before 1993 were excluded. The years of
diagnoses were categorized as 1993–1998, 1999–2003,
2004–2008, and 2009–2013.
The primary objective was to analyze time trends in the
incidence of AF. Trends of clinicopathological factors were
analyzed as well as possible associations between the
factors. The secondary objective was to analyze time trends
in type of treatment, to which end the rate of resection was
evaluated. Due to constrains in the pathology database
structure, only data on pathology specimens, such as biopsy
of resection were available. Information on other treatment
strategies or outcome was not available.
In order to compare the patient cohort with the Dutch
population, data from Statistics Netherlands were obtained.
This is a registry for all general population data. We used
information on demographics to calculate annual incidence
rates and information on surgical treatments, hormonal
drugs, and newborns to analyze possible etiological
correlations.
Statistical Analysis
Statistical analysis was performed using IBM SPSS
Statistics 21. Continuous variables are shown as median
and interquartile range (IQR), and categorical variables as
numbers with percentages. Associations between clinico-
pathological variables were determined by v2 analysis.
Univariate logistic and linear regression analysis was per-
formed to analyze trends over time. Results are shown as
odds ratios (OR) or regression coefficient B (B) and with
95 % confidence intervals (CI). For all analyses, two-sided
P\ 0.050 was considered statistically significant.
RESULTS
A total of 1134 patients were diagnosed with extra-ab-
dominal or abdominal wall AF between January 1993 and
December 2013; there were 326 men and 808 women.
Median age was 37 years [interquartile range (IQR) 30–
50]. The distribution of demographic factors is shown in
Table 1.
In addition to the 1134 patients diagnosed as having AF,
an uncertain diagnosis of AF was stated in the pathology
excerpt in 213 patients. This latter group of patients did not
change significantly over the years (P = 0.730). These
patients were not included in the analyses for the present
series.
Epidemiologic Factors
The incidence of extra-abdominal and abdominal wall
AF increased over the study period, from 2.10 to 5.36 per
one million people (P\ 0.001; Fig. 1).
Age
The median age increased annually by B 0.285 (95 % CI
0.114–0.455; P = 0.001). The median age in 1993–1998
was 34 years (range 27–45) and was 39 years (range 30–
51) in 2009–2013. The absolute numbers increased in all
age groups over time (Fig. 2a). However, the percentage of
patients per age groups changed, mostly in patients aged
20–79 years (Fig. 2b). Analysis of the distribution among
age groups showed a significant annual decrease in the
percentage of patients aged 20–45 years (OR 0.977; 95 %
CI 0.957–0.997; P = 0.027) and a trend towards an annual
increase in the percentage of patients aged 45–65 years and
65–80 years (OR 1.017; 95 % CI 0.993–1.042; P = 0.173
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and OR 1.035; 95 % CI 0.997–1.074; P = 0.069
respectively).
Gender
The absolute numbers of both male and female patients
increased over the years. The male–female ratio showed an
increasing female predominance, ranging from 68.6 % in
1993–1998 to 73.6 % in 2009–2013.
Anatomic Tumor Localization
Tumor localization was distributed as: 6.7 % head/neck,
29.0 % trunk, 38.6 % abdominal wall, 20.7 % extremity, and
5.1 % other (localization details were missing for 22
patients). Over the years, the absolute incidence in all groups
increased (Fig. 2c). Analysis of the distribution of tumor
localization showed a significant proportional increase in the
percentage of patients with truncal localization (OR 1.057;
95 % CI 1.032–1.083;P\ 0.001), whereas the percentage of
patients with tumors in the abdominal wall decreased (OR
0.972; 95 % CI 0.952–0.993; P = 0.008).
Associations Between Clinicopathological Factors
The distribution of tumor localization varied per age
group (Fig. 2d). Extremity-based tumors were most com-
mon in patients younger than 20 years of age (45.0 %),
whereas patients between 20 and 45 years most commonly
harbored abdominal wall tumors (52.6 %); truncal tumors
were predominantly seen in patients between 45 and
80 years of age (41.5 %). For patients older than 80 years
of age, no dominant localization could be identified. The
TABLE 1 Distribution of epidemiologic factors
1993–1998 1999–2003 2004–2008 2009–2013
N % N % N % N %
Gender
Male 56 31.1 50 27.0 105 31.7 115 26.3
Female 124 68.9 135 73.0 226 68.3 323 73.7
Age (year)
\20 18 10.0 14 7.6 29 8.8 39 8.9
20–44 115 63.9 124 67.0 170 51.4 239 54.6
45–64 37 20.6 33 17.8 85 25.7 112 25.6
65–79 10 5.6 11 5.9 39 11.8 43 9.8
80? 0 0 3 1.6 8 2.4 5 1.1
Localization
Head/neck 14 8.0 13 7.1 20 6.1 27 6.2
Trunk 29 16.7 39 21.4 102 30.9 152 34.8
Abdominal wall 77 44.3 88 48.4 113 34.2 151 34.6
Extremity 45 25.9 32 17.6 68 20.6 85 19.5
Other 7 4.0 6 3.3 22 6.7 22 5.0
Unknown 2 1.1 4 2.2 5 1.5 0 0
Pathology reports
Biopsy 13 7.2 39 21.1 69 20.8 130 29.7
Biopsy ? resection 39 21.7 40 21.6 98 29.6 161 36.8
Resection 114 63.3 101 54.6 163 49.2 147 33.6
Unknown 14 7.8 5 2.7 1 0.3 0 0
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FIG. 1 Incidence of aggressive fibromatosis, per million people
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distribution of age groups and localization changed over
the study period.
Workup and Treatment
In 251 patients (22.1 %) solely a biopsy report was
retrieved; for 338 patients (29.8 %) a biopsy report and a
pathology resection specimen report was retrieved, and for
525 patients (46.3 %) solely a pathology resection speci-
men report was retrieved. For 20 patients, the type of report
was unknown (Fig. 3). From 1993–1998 to 2008–2013, the
biopsy rate increased more than twofold: from 31.1 to
66.4 % (OR 1.096; 95 % CI 1.072–1.121, P\ 0.001). The
proportion of patients who underwent surgical resection
decreased annually (OR 0.928; 95 % CI 0.902–0.954,
P\ 0.001). It was not known what treatment was offered
to the patients who did not undergo surgery due to the
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nature of the database. Over time, surgical resection was
increasingly preceded by biopsy. If a resection was pre-
ceded by biopsy, the resection margin status improved
significantly (49.8 % R0-resection vs. 30.7 % in patients
without biopsy; P\ 0.001). Pathology reports did not
discriminate between diagnostic or therapeutic resections.
Median time between biopsy and resection was 1.6 months
(IQR 0.9–2.7). The date of either biopsy or resection was
missing for two patients. A substantial number of patients
(210; 18.5 %) had a history of surgery in the same area
where AF subsequently developed.
Dutch Population
Since the abdominal wall was the most common tumor
localization, we analyzed surgical trends in the Netherlands
for the most common surgeries in this area (caesarean
section, cholecystectomy, appendectomy, and colec-
tomy).24 During the study period, surgical trauma to the
abdominal wall increased (Figs. 4, 5). Due to minimal
invasive techniques for many surgical interventions, the
rate of laparotomy decreased and the rate of laparoscopic
surgery increased.
Data on hormonal drugs was available for the period
2006–2012. During this period, the overall use of hormonal
medication in the Netherlands remained stable.
The number of pregnancies of any gestational age was
not available. The number of newborns per year was used
as a surrogate, and during the study period this number
decreased from 195.748 in 1993 to 171.341 in 2013.
DISCUSSION
The reference standard on the incidence and epidemi-
ology of AF are Finnish studies by Reitamo et al.6–8 An
incidence of 2.4–4.3 per million people was reported in
those studies, using three methods of estimation (local,
regional, and national). Distribution of disease was repor-
ted with a dominance of abdominal wall tumors (49 %)
with variations per age groups. In the present population
based study, a rising incidence of extra-abdominal and
abdominal wall AF was observed from 2.1 to 5.36 per
million people during the period 1993–2013. The distri-
bution among age groups was similar to the Finnish
studies, with a predominance of abdominal wall tumors in
females aged 20–44 years. Remarkably, median age and
female predominance increased over the years and the
distribution of tumor localization shifted. The driving
factor for these observed changes is unclear.
The PALGA database provided an elaborate overview
of AF in the Netherlands. The nationwide coverage enabled
epidemiological research on this rare disease. Then again,
the available information was limited to the date and
conclusion of the pathology reports. Although there was
information on biopsy and resection, no information was
available for nonsurgical treatments, which is a limitation
of the present study. Still, important information could be
extracted.
Time Trends in Incidence
Explanations for the observed rising incidence of AF are
not evident. If an increase in incidence occurs, this can be
due to improved diagnostic modalities (i.e., for instance
detection of previously unrecognized tumors by improved
imaging, improved recognition of the disease by patholo-
gists, or the start of a screening program) or due to a true
increase in the incidence of the disease.
Improved registration and diagnostic tools are likely to
have influenced the incidence figures to some extent. The
changes in distribution of tumor localization might be an
indication for a true change in disease. However, there are
possible biases: other reasons could be an increased fre-
quency of trunk computer-tomography scan or higher
awareness due to screening programs.
Dutch guidelines on registration of neoplasms have
changed over the years. The introduction of the third edi-
tion of the WHO Classification for Soft Tissue and Bone
Tumours stimulated improvement of coding, enabling a
better pathology registration.25 Due to the benign nature,
this neoplasm is not registered among soft tissue tumors in
the national cancer registries precluding verification of our
data. The overall incidence of sarcomas has remained
stable over the years at approximately 30–35 patients per
million people, with a slight increase to around 40 patients
per million people over the past 5 years.26
Knowledge on b-catenin and its application in the
diagnostic setting around 2005 aided the pathologist in
diagnosing AF with more confidence.27–29 Nevertheless,
the percentage of uncertain diagnoses has not changed
significantly over the years, indicating that some difficulty
to distinguish AF from low-grade and reactive spindle cell
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FIG. 5 Abdominal surgery in the Netherlands
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proliferations remains. Awareness of the presence of AF
and the realization of the importance of a correct diagnosis
have improved. In addition, the association with FAP is
better understood. Lastly, screening programs may have
influenced the stage of diagnosis, such as the breast cancer
screening program in asymptomatic people.
Documented etiological factors are surgical trauma,
hormonal influences, and pregnancy.6–8 National data on
these factors was obtained to provide some context for the
study data. A hypothesis could be that the increased rate of
surgical trauma would lead to an increase in AF. On the
contrary, a limitation of surgical trauma by means of
minimal invasive techniques could possibly decrease the
risk of AF. The analyses of abdominal surgery and
abdominal AF both showed increasing rates over the study
period, which might be supportive of the first hypothesis.
The peak in occurrence of AF among fertile females is
supportive of hormonal influences as an etiological factor.
To test the hypothesis that a rise in hormonal levels would
lead to an increase in AF, we compared data on hormonal
drug use from Statistics Netherlands with the data from
PALGA. Although the information on drug use was from a
small period (2006–2012), the incidence of AF was rising
during this period while the rate of hormonal drug use
remained stable.
Pregnancy is seen as an etiological factor within the
hormonal influences. Because no data on pregnancies in the
patient cohort were available, we obtained the rate of
newborns in the Netherlands during the study period. The
rate of pregnancies of any gestational age was not avail-
able. The hypothesis that an increase in pregnancies
(represented by the number of newborns) would lead to an
increase in AF was not supported, as the rate of newborns
was decreasing.
A more sensitive approach to test hormonal influences
on AF, like analyzing hormonal receptors on the tumor,
could provide more information but was not possible for
the current study.
We would like to emphasize that the presented com-
parisons between data from PALGA and Statistics
Netherlands are all based on hypotheses. Direct correla-
tions for these etiological factors could not be explored and
possible biases should be taken into consideration.
Time Trends in Diagnosis and Treatment
Despite the aforementioned advances in diagnostic
tools, the diagnosis of AF poses remaining challenges to
the treating physicians. Although the rising incidence is
most likely biased by diagnostic modalities and improved
registration, the presented results showed an increasing
number of patients being treated for AF.
The presented results suggest an improved workup
procedure of patients as histological biopsies were more
often obtained. Surgical resection following a biopsy
diagnosis resulted in a significant higher rate of negative
resection margins, underscoring the importance of the
diagnostic process.
Treatment strategies changed in recent years and this is
reflected in the present data. There has been a paradigm
shift in the surgical treatment for AF patients. Before 2000,
surgery with negative margins had been considered the
standard of care for patients affected by AF, reflecting the
same approach to extremity soft-tissue sarcomas. A
reassessment has taken place by several groups, advocating
a more conservative approach.30,31 The European consen-
sus is currently set at an initial wait-and-see approach.32
The increasing number of patients undergoing nonsurgical
treatment in the presented study indicated a tendency to
adhere to this policy in the Netherlands. The growing
knowledge and understanding of the etiology and
involvement of CTNNB1-mutations will improve the
diagnostic process.
During the past 25 years, developments in the available
diagnostic modalities and changing treatment insights had
an impact on the workup and treatment of extra-abdominal
and abdominal wall AF. More insight in current epidemi-
ologic trends and treatment-related trends was imperative.
This population-based study reflected these changes and
showed an overall incidence rise of AF. The reasons for the
changing incidence, age distribution, and anatomic local-
ization distribution remain to be further elucidated.
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